mobile phase comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-20. Numbers and descriptions here follow the published literature rather than marketing material.
Most routine HPLC testing uses reversed-phase columns, where the stationary phase is nonpolar and the mobile phase is a polar mixture such as water with an organic solvent. Analytes partition between the two phases according to polarity, size, and charge. Gradients that change solvent composition over time can separate compounds with broad retention ranges. Isocratic conditions keep solvent composition constant and suit simpler mixtures. The choice of column chemistry, pH, and temperature affects selectivity and peak shape.
Detection in HPLC testing commonly relies on ultraviolet-visible absorbance, fluorescence, refractive index, or mass spectrometry. UV detection is widely used because many organic compounds absorb light, but it requires a chromophore. Mass spectrometry provides mass-based identification and high sensitivity for trace analytes. Each detector has trade-offs in selectivity, cost, and compatibility with mobile phases. Quantification typically uses calibration curves prepared from reference standards. Results are reported as concentration, purity, or presence above a limit.
Developing an HPLC test begins with defining the analytes, matrix, and required reporting limits. Chemists select a separation mode, column chemistry, mobile phase composition, flow rate, and detection wavelength or mass transition. Experiments then adjust these variables to achieve adequate retention, resolution, and peak shape. System suitability tests confirm that the instrument and method perform consistently before sample analysis. Without suitable resolution, quantitative results may be unreliable. Preliminary runs often use scouting gradients to locate retention windows.
Validation establishes that a method is suitable for its intended purpose. Typical parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantification, robustness, and stability of standards and samples. Acceptance criteria are defined in advance, and results are documented in a validation report. Regulatory guidance for pharmaceuticals, foods, and environmental testing differs, so the applicable framework must be identified. Ongoing verification uses control samples and trend charts after validation. Method transfer to another laboratory may require partial revalidation.
| Property | Value | Notes |
|---|---|---|
| Separation mode | Reversed-phase | Nonpolar stationary phase with polar mobile phase |
| Typical column particle size | 3–5 µm | Smaller particles improve resolution but raise pressure |
| Typical flow rate | 0.5–2.0 mL/min | Depends on column dimensions and pressure limits |
| Common detection | UV-Vis absorbance | Requires analytes with chromophores |
| Typical run time | 5–30 min | Varies with method, gradient, and sample complexity |
Several separation modes exist, including reversed-phase, normal-phase, ion-exchange, size-exclusion, and hydrophilic interaction liquid chromatography. Reversed-phase uses a nonpolar stationary phase with a polar mobile phase and is widely applied to small organic molecules. Gradient elution changes mobile phase composition during the run, while isocratic elution keeps it constant. Column chemistry, particle size, temperature, flow rate, and mobile phase pH all influence retention and resolution. Method development selects conditions that separate analytes from matrix components and from each other.
Detection commonly uses ultraviolet-visible absorbance, fluorescence, refractive index, or mass spectrometry. Ultraviolet detection depends on molecular chromophores that absorb light at specific wavelengths. Mass spectrometry provides mass information and sensitive quantification, often after electrospray ionization. Before sample batches, performance checks examine resolution, elution time repeatability, peak symmetry, and plate count. Matrix effects and co-elution remain recognized uncertainties; formal validation studies and orthogonal detection help address them. Detector choice depends on analyte properties and required sensitivity.
High-performance liquid chromatography, or HPLC, separates dissolved compounds by passing a liquid mobile phase through a packed column. Components distribute differently between the stationary phase and the moving liquid, so they travel at different speeds and exit at different times. A detector records these eluting bands as peaks, and peak area or height relates to amount. The technique supports testing in pharmaceuticals, foods, environmental samples, and industrial chemicals. Quantification usually depends on calibration with known standards.
Method validation establishes that an HPLC procedure is suitable for its intended purpose. Typical parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, robustness, and solution stability. Accuracy reflects closeness to a reference value, while precision reflects agreement among repeated measurements. Specificity shows whether the method can measure the analyte without interference from matrix components. Validation is documented through protocols and reports, and the required extent depends on the method's use and regulatory context.
Routine quality control uses system suitability, blank injections, check standards, and control samples to detect drift or contamination. System suitability criteria may specify minimum resolution, maximum tailing factor, and a permitted range for repeated injections. Blank injections reveal carryover or solvent contamination, while check standards confirm calibration accuracy over a batch. Control samples with known analyte levels can show whether results remain within statistical limits. When a control result falls outside limits, the analyst investigates the cause and may invalidate affected results before repeating the batch.
Documentation and traceability are central to regulated HPLC testing. Records typically include instrument logs, column history, mobile-phase preparation, sample preparation, injection sequences, raw chromatograms, and audit trails. Electronic systems may require user access controls, time-stamped changes, and backup procedures. Training records show that analysts are qualified for assigned methods. Audits and inspections check whether written procedures match actual practice and whether deviations are documented. These controls support reproducibility and allow results to be reconstructed if questions arise later.
Method validation establishes that an HPLC procedure is suitable for its intended use. Key parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Accuracy measures agreement with a true or accepted value, while precision describes repeatability and intermediate precision. Specificity confirms that the method measures the analyte without interference from impurities, degradants, or excipients. Validation is documented in a protocol and report, and acceptance criteria are set before experiments begin. Regulatory guidance varies by region, but the general principles are widely harmonized.
System suitability testing is performed before and during analytical runs to confirm that the instrument and method are working as expected. Common checks include retention time, peak area, resolution between critical pairs, tailing factor, and theoretical plate count. Results are compared with predefined limits, and a failed check requires investigation before sample results are reported. Quality control samples at low, middle, and high concentrations are injected at intervals to monitor accuracy and precision. Blank injections detect carryover and contamination, while control charts track performance over time.
Data handling and documentation are central to HPLC quality control. Electronic systems should have audit trails that record changes to methods, sequences, and results. Integration parameters, such as peak baseline and threshold, can affect reported areas and must be defined in advance. Out-of-specification results trigger a structured investigation that may include reanalysis, instrument checks, and review of sample preparation. Regulatory inspections often examine raw data, audit trails, and training records to verify that reported results are traceable and reliable.
=== Scalp conditions === Dandruff – a common problem caused by excessive shedding of dead skin cells from the scalp Head lice infestation Excoriation disorder – obsessive skin picking Trichotillomania – obsessive hair pulling Seborrhoeic dermatitis – a skin disorder causing scaly, flaky, itchy, red skin Cradle cap – a form of seborrhoeic dermatitis which occurs in newborns Trichodynia – burning scalp syndrome Tinea capitis - ringworm of the scalp, and its severe form Favus Cutis verticis gyrata – a rare deformity of the scalp
A diagnosis of rhabdomyolysis may be suspected in anyone who has sustained trauma, crush injury or prolonged immobilization, but it may also be identified at a later stage due to deteriorating kidney function (abnormally raised or increasing creatinine and urea levels, falling urine output) or reddish-brown discoloration of the urine. The most reliable test in the diagnosis of rhabdomyolysis is the level of creatine kinase (CK) in the blood. This enzyme is released by damaged muscle, and levels above 1000 U/L (5 times the upper limit of normal (ULN)) indicate rhabdomyolysis. More than 5000 U/L indicates severe disease, but depending on the extent of the rhabdomyolysis, concentrations up to 100000 U/l are not unusual. CK concentrations rise steadily for 12 hours after the original muscle injury, remain elevated for 1–3 days and then fall gradually. Initial and peak CK levels have a linear relationship with the risk of acute kidney failure: the higher the CK, the more likely it is that kidney damage will occur. There is no specific concentration of CK above which kidney impairment definitely occurs; concentrations below 20000 U/L are unlikely to be associated with a risk of kidney impairment, unless there are other contributing risk factors. Mild rises without kidney impairment are referred to as "hyperCKemia". Myoglobin has a short half-life, and is therefore less useful as a diagnostic test in the later stages. Its detection in blood or urine is associated with a higher risk of kidney impairment.
In early April, Sykes and Picot were appointed to act as the chief negotiators once more, this time on a month-long mission to the Middle East for further discussions with the Sherif of Mecca and other Arab leaders. On 3 April 1917, Sykes met with Lloyd George, Lord Curzon and Maurice Hankey to receive his instructions in this regard, namely to keep the French onside while "not prejudicing the Zionist movement and the possibility of its development under British auspices, [and not] enter into any political pledges to the Arabs, and particularly none in regard to Palestine". Before travelling to the Middle East, Picot, via Sykes, invited Nahum Sokolow to Paris to educate the French government on Zionism. Sykes, who had prepared the way in correspondence with Picot, arrived a few days after Sokolow; in the meantime, Sokolow had met Picot and other French officials, and convinced the French Foreign Office to accept for study a statement of Zionist aims "in regard to facilities of colonization, communal autonomy, rights of language and establishment of a Jewish chartered company." Sykes went on ahead to Italy and had meetings with the British ambassador and British Vatican representative to prepare the way for Sokolow once again. Sokolow was granted an audience with Pope Benedict XV on 6 May 1917. Sokolow's notes of the meeting – the only meeting records known to historians – stated that the Pope expressed general sympathy and support for the Zionist project.
Sources: en.wikipedia.org
In North America: Alphora, Delmar and NAEJA, all Canada. AMRI, Aptuit, Cambridge Major, ChemBridge, Innocentive, Irix Pharmaceuticals and PharmEco, all USA. In Europe: Carbogen-Amcis, Switzerland; Chemcomm, Germany; ChemDiv, Russia; Clauson-Kaas, Denmark; Enamine Ltd, Ukraine; Girindus, Germany; Nerviano Medical Sciences, Italy; Recipharm, Sweden; Serichim, Italy; Solvias, Switzerland, Netherlands. In Asia: BioDuro, Medicilon, Pharmaron and WuXi AppTec, all China; Acoris, Aptuit Laurus, Biocon/Syngene, Chembiotek, Chempartner and ProCitius, all India; NARD Institute and Riken, both Japan. The business of CROs is usually done through a "pay for service" arrangement. Unlike manufacturing companies, invoicing of CROs is not based on unit product price, but on full-time equivalents (FTEs), or the cost of a scientist working one year on a given customer assignment. Companies offering both contract research and manufacturing services (CRAMS) combine the activities of CROs and CMOs. Their history is either a forward integration of a CRO, which adds industrial scale capabilities, or backwards integration of a CMO. As there are only limited synergies (>90% of the projects end at the sample preparation stage), it is questionable if one-stop shops really fulfil a need. Large fine chemical companies consider the preparation of samples more as marketing tool (and expense) rather than a profit contributor.
== Complications == One review of 23 publications involved a total of 889 patients reported an overall rate of complications of 18%. Reported complications are mostly minor, and include: bleeding, perianal pain / discomfort (which may rarely be persistent), leakage of injected material, infection / abscess (which rarely may require drainage), mucosal erosion, obstructed defecation, hypersensitivity reaction, hematoma, diarrhea, pruritus ani, dermatitis, and bowel urgency (sudden strong urge to defecate).
Sinosauropteryx was the first non-avian dinosaur to have its life colouration described by scientists based on physical evidence. Some fossils of Sinosauropteryx show an alternation of lighter and darker bands preserved on the tail. Chen and colleagues initially interpreted this banding pattern as an artifact of the splitting between the main slab and counter slab in which the original specimen was preserved. However, Longrich suggested in his 2002 presentation for the Society of Vertebrate Paleontology that these specimens actually preserve remnants of the colouration pattern the animal would have exhibited in life. He argued that the dark, banded areas on the tail were too evenly spaced to have been caused by random separation of the fossil slabs, and that they represent fossilized pigments present in the feathers. Additionally, rather than an artifact of preservation or decomposition, the presence of dark feathers along only the top of the body may also reflect the colour pattern in life, indicating that Sinosauropteryx prima was countershaded with dark colouration on its back and lighter colouration on its underside, with bands or stripes on the tail for camouflage. Longrich's conclusions were supported in a paper first published online in the journal Nature in January 2010. Fucheng Zhang and colleagues examined the fossilized feathers of several dinosaurs and early birds, and found evidence that they preserved melanosomes, the cell components that give the feathers of modern birds their colour.
=== Physiological roles in organs and tissues === FcRn is expressed on antigen-presenting leukocytes such as dendritic cells and is also expressed in neutrophils to help clear opsonized bacteria. In the kidneys, FcRn is expressed on epithelial cells called podocytes to prevent IgG and albumin from clogging the glomerular filtration barrier. Current studies are investigating FcRn in the liver because there are relatively low concentrations of both IgG and albumin in liver bile despite high concentrations in the blood. Studies have also shown that FcRn-mediated transcytosis is involved with the trafficking of the HIV-1 virus across genital tract epithelium.
Sources: en.wikipedia.org
It separates components in a liquid sample and measures their amounts using a detector. Results can indicate concentration, purity, or identity based on retention time and detector response. The technique works for mixtures that can be dissolved and filtered.
It offers high resolution, reproducibility, and compatibility with many sample types. A single run can separate and quantify multiple analytes. It is common in pharmaceutical, food, environmental, and industrial laboratories.
Samples must be soluble in a suitable mobile phase and free of particles that can block the column. Detector response depends on analyte structure, so some compounds need derivatization or alternative detection. Complex matrices may require extensive sample preparation.
System suitability is a set of checks performed before and during a run to confirm that the instrument, column, and method work as expected. Common checks include resolution, tailing factor, theoretical plates, and relative standard deviation of replicate injections. Failure triggers troubleshooting or method adjustment.